BridgeMD
New treatment option for Systemic Lupus Erythematosus
Official title A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
ClinicalTrials.gov ID: NCT07430306
What this study is testing
What is Anifrolumab?
Anifrolumab is an investigational medicine, given as an once-weekly injection under the skin, being studied as a potential treatment for systemic lupus erythematosus.
Also referred to as Saphnelo.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of the SUNFLOWER study is to describe clinical outcomes, including DORIS remission, achieved following the initiation of anifrolumab 120 mg SC once weekly (QW) as add-on therapy to an anti-malarial, with or without GC; in patients not in LLDAS at enrolment. Patients will be naïve to any prior conventional immunosuppressant including prior biologic therapy at enrolment.
- Phase 3: a large, late-stage study
- Time commitment: about 12 weeks
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 70
You may be able to join if
- Males or females aged 18 to 70 years of age.
- Participants who have a diagnosis of SLE confirmed by a rheumatologist.
- ANA-positive per the Central Lab at screening: (a) ANA (b) Anti-dsDNA (c) Anti-Smith (anti-Sm)
- Must be on the standard therapy regimen: antimalarials with or without OCSs
- Must have at screening and baseline:
You likely can't join if
- people with history of, or current diagnosis of, a clinically significant non-SLE related vasculitis syndrome.
- people with antiphospholipid antibody syndrome on stable anticoagulant therapy at an effective dose (e.g., if on warfarin, an international...
- people with a serious thrombotic event (e.g., pulmonary embolism stroke, deep vein thrombosis) or unexplained pregnancy loss within 1 year before the...
- people with a history of catastrophic antiphospholipid syndrome or saddle embolism.
- people with a history of 3 or more unexplained consecutive pregnancy losses.
- History or evidence of suicidal ideation within the past 6 months; or any suicidal behavior within the past 12 months or recurrent suicidal behavior...
See the full eligibility criteria
Who can join
- Males or females aged 18 to 70 years of age.
- Participants who have a diagnosis of SLE confirmed by a rheumatologist.
- ANA-positive per the Central Lab at screening: (a) ANA (b) Anti-dsDNA (c) Anti-Smith (anti-Sm)
- Must be on the standard therapy regimen: antimalarials with or without OCSs
- Must have at screening and baseline:
- Clinical SLEDAI-2K ≥ 4 points OR
- Clinical SLEDAI-2K \< 4 with GC dose ≥ 7.5 mg/day (prednisone equivalent)
- Should have no evidence of current active infection, (e.g., pneumonia, tuberculosis [TB]) or previous TB
- Should have no evidence of malignancy; and clinically significant abnormalities (unless due to SLE).
- No medical history or signs or symptoms of active TB prior to or during Screening.
- Body weight ≥ 40.0 kg
- Negative pregnancy test for females during screening
- Normal HPV test result within 2 years prior to Week 0 (Day 1).
- Willing and able to participate in all required study evaluations and procedures including completion of PROs.
- Willing to not use any other forms of experimental treatment during the study.
What rules you out
- people with history of, or current diagnosis of, a clinically significant non-SLE related vasculitis syndrome.
- people with antiphospholipid antibody syndrome on stable anticoagulant therapy at an effective dose (e.g., if on warfarin, an international normalized ratio [INR] target 2 to 3 or as appropriate for the clinical...
- people with a serious thrombotic event (e.g., pulmonary embolism stroke, deep vein thrombosis) or unexplained pregnancy loss within 1 year before the screening visit are excluded.
- people with a history of catastrophic antiphospholipid syndrome or saddle embolism.
- people with a history of 3 or more unexplained consecutive pregnancy losses.
- History or evidence of suicidal ideation within the past 6 months; or any suicidal behavior within the past 12 months or recurrent suicidal behavior in the lifetime of the participant based on an assessment with the...
- Active severe or unstable neuropsychiatric SLE including, but not limited to aseptic meningitis, cerebral vasculitis, myelopathy, demyelination syndromes (ascending, transverse, acute inflammatory demyelinating...
- Active severe SLE-driven renal disease where, protocol-specified standard therapy is insufficient.
- Current diagnosis of, catastrophic antiphospholipid syndrome (APS).
- History of recurrent infection requiring hospitalization and IV antibiotics (e.g., 3 or more of the same type of infection over the previous 52 weeks).
- Known History of a primary immunodeficiency, splenectomy, or any underlying condition that predisposes the participant to infection, or a positive result for HIV at Screening.
- Confirmed positive test for hepatitis B.
- Any clinical cytomegalovirus (CMV) or Epstein-Barr virus (EBV) infection that has not completely resolved within 12 weeks prior to signing the ICF.
- Opportunistic infection requiring hospitalization or IV antimicrobial treatment within 3 years of Week 0 (Day 1).
- Clinically significant chronic infection (e.g., osteomyelitis, bronchiectasis, etc.) within 8 weeks prior to signing the ICF (chronic nail infections are allowed).
- Severe HZ or recurrent HZ.
- Malignancy. History of cancer, apart from: (a) Squamous or basal cell carcinoma of the skin treated with documented success of curative therapy ≥ 3 months prior to Week 0 (Day 1). (a) Cervical cancer in situ treated...
- Received any SLE-related therapies other than antimalarials and GCs.
- History of allergy or reaction to any component of the study intervention formulation or history of anaphylaxis to any human gamma globulin therapy.
- History of an anaphylactic reaction to human proteins or mAbs.
- Received any live or attenuated vaccine within 8 weeks prior to signing the ICF.
- Blood transfusion or receipt of blood products except albumin.
- Received more than 2 investigational products for the SLE since time of diagnosis.
- Received any investigational product (small molecule or biologic agent) within 4 weeks or 5 half-lives prior to signing of the ICF, whichever is greater.
- Concurrent enrollment in another clinical study with a study intervention.
- people with any abnormal lab result as specified in the protocol.
- people with other autoimmune diseases (e.g., multiple sclerosis, psoriasis, IBD, etc.).
- people with SLE overlap syndromes such as scleroderma and mixed connective tissue disease.
- Subject with non-SLE concomitant illness, as determined by medical judgment, who is likely to require additional systemic glucocorticosteroid therapy during the study (e.g., asthma).
- Any condition would interfere with treatment outcomes of the study intervention or put participant at safety risk.
- Lactating, breastfeeding, or pregnant females or females who intend to become pregnant or begin breastfeeding anytime from initiation of Screening until 16 weeks following last dose of study intervention.
- Spontaneous or induced abortion, still or live birth, or pregnancy ≤ 4 weeks prior to signing the ICF.
- Current alcohol, drug or chemical abuse, or a history of such abuse within 1 year before Week 0 (Day 1).
- Major surgery within 8 weeks before signing the ICF or elective major surgery planned during the study period.
The study team makes the final eligibility decision.
Where it's taking place
- Anniston, Alabama, United States
- Birmingham, Alabama, United States
- Phoenix, Arizona, United States
- Tucson, Arizona, United States
- Fontana, California, United States
- La Jolla, California, United States
- La Palma, California, United States
- Menifee, California, United States
- San Leandro, California, United States
- Temecula, California, United States
- Brandon, Florida, United States
- Miami, Florida, United States
- Willowbrook, Illinois, United States
- New Albany, Indiana, United States
- Lake Charles, Louisiana, United States
- Kansas City, Missouri, United States
- Oklahoma City, Oklahoma, United States
- Memphis, Tennessee, United States
- Austin, Texas, United States
- Baytown, Texas, United States
+ 62 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 12 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Anniston, Alabama, United States; Birmingham, Alabama, United States; Phoenix, Arizona, United States; Tucson, Arizona, United States; Fontana, California, United States; La Jolla, California, United States and 76 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.